All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the Lymphoma Coalition.
The Lymphoma Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy
Introducing
Now you can personalise
your Lymphoma Hub experience!
Bookmark content to read later
Select your specific areas of interest
View content recommended for you
Find out moreThe Lymphoma Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the Lymphoma Hub cannot guarantee the accuracy of translated content. The Lymphoma Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The Lymphoma & CLL Hub is an independent medical education platform, sponsored by Beigene and Roche, and supported through educational grants from Bristol Myers Squibb, Ipsen Biopharmaceuticals, Lilly, Pfizer, and Pharmacyclics LLC, an AbbVie Company and Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC View funders.
Update from SOHO 2020 on follicular lymphoma
Bookmark this article
During the 2020 Annual Meeting of the Society of Hematologic Oncology (SOHO), the Lymphoma Hub was pleased to speak to Steering Committee member Nathan Fowler, MD Anderson Cancer Center, Houston, US. In this interview he provided an update on follicular lymphoma from the SOHO 2020 Meeting.
Update from SOHO 2020 on follicular lymphoma
Nathan Fowler first outlines the recent advances in the management of patients with newly diagnosed indolent lymphoma. He highlights the superiority in progression-free survival observed in patients receiving obinutuzumab + chemotherapy over rituximab + chemotherapy. He also discusses the results from the RELEVANCE trial, evaluating lenalidomide + rituximab vs rituximab + chemotherapy.
In the relapsed setting, several novel agents have been approved by the FDA in recent years, including PI3K inhibitors, lenalidomide in combination with rituximab, and the first-in-class EZH2 inhibitor, tazemetostat.
Understanding your specialty helps us to deliver the most relevant and engaging content.
Please spare a moment to share yours.
Please select or type your specialty
Thank youYour opinion matters
42 votes - 80 days left ...
Related articles
Newsletter
Subscribe to get the best content related to lymphoma & CLL delivered to your inbox